308 related articles for article (PubMed ID: 23067322)
1. The single pill triple combination of aliskiren, amlodipine, and hydrochlorothiazide in the treatment of hypertension.
Huan Y; Townsend R
Expert Opin Pharmacother; 2012 Nov; 13(16):2409-15. PubMed ID: 23067322
[TBL] [Abstract][Full Text] [Related]
2. Single-pill triple-combination therapy: an alternative to multiple-drug treatment of hypertension.
Chrysant SG
Postgrad Med; 2011 Nov; 123(6):21-31. PubMed ID: 22104451
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of aliskiren 300 mg/hydrochlorothiazide 25 mg (± amlodipine 5 mg) in hypertensive patients not controlled by candesartan 32 mg plus HCT 25 mg.
Schweizer J; Ulmer HJ; Benduhn H; Klebs S
Curr Med Res Opin; 2011 Jan; 27(1):131-40. PubMed ID: 21117946
[TBL] [Abstract][Full Text] [Related]
4. Clinic and ambulatory blood pressure lowering effect of aliskiren/amlodipine/hydrochlorothiazide combination in patients with moderate-to-severe hypertension: a randomized active-controlled trial.
Lacourcière Y; Taddei S; Konis G; Fang H; Severin T; Zhang J
J Hypertens; 2012 Oct; 30(10):2047-55. PubMed ID: 22828090
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of aliskiren/hydrochlorothiazide single-pill combination tablets and free combination of aliskiren and hydrochlorothiazide.
Yan JH; Jarugula V; Sabo R; Papst CC; Zhang J; Dole WP
J Clin Pharmacol; 2012 May; 52(5):645-55. PubMed ID: 21659626
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of the single-pill combination of aliskiren 300 mg/amlodipine 10 mg in hypertensive patients not controlled by olmesartan 40 mg/amlodipine 10 mg.
Axthelm C; Sieder C; Meister F; Kaiser E
Curr Med Res Opin; 2012 Jan; 28(1):69-78. PubMed ID: 22117838
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of aliskiren-based dual and triple combination therapies in US minority patients with stage 2 hypertension.
Ferdinand KC; Weitzman R; Israel M; Lee J; Purkayastha D; Jaimes EA
J Am Soc Hypertens; 2011; 5(2):102-13. PubMed ID: 21414565
[TBL] [Abstract][Full Text] [Related]
8. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide.
Schmieder RE; Philipp T; Guerediaga J; Gorostidi M; Smith B; Weissbach N; Maboudian M; Botha J; van Ingen H
Circulation; 2009 Jan; 119(3):417-25. PubMed ID: 19139391
[TBL] [Abstract][Full Text] [Related]
9. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
[TBL] [Abstract][Full Text] [Related]
10. Aliskiren-based dual- and triple-combination therapies in high-risk US minority patients with stage 2 hypertension.
Ferdinand KC; Weitzman R; Purkayastha D; Sridharan K; Jaimes EA
J Am Soc Hypertens; 2012; 6(3):219-27. PubMed ID: 22305998
[TBL] [Abstract][Full Text] [Related]
11. Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension.
Judd E; Jaimes EA
Expert Rev Cardiovasc Ther; 2012 Mar; 10(3):293-303. PubMed ID: 22390800
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with aliskiren and amlodipine in hypertension: treatment rationale and clinical results.
Zion AS; Izzo JL
Expert Rev Cardiovasc Ther; 2011 Apr; 9(4):421-7. PubMed ID: 21417713
[TBL] [Abstract][Full Text] [Related]
13. Comparison of aliskiren/hydrochlorothiazide combination therapy and amlodipine monotherapy in patients with stage 2 systolic hypertension and type 2 diabetes mellitus.
Townsend RR; Forker AD; Bhosekar V; Yadao A; Keefe DL
J Clin Hypertens (Greenwich); 2011 Dec; 13(12):889-97. PubMed ID: 22142348
[TBL] [Abstract][Full Text] [Related]
14. Triple combination therapy to improve blood pressure control: experience with olmesartan-amlodipine-hydrochlorothiazide therapy.
Tocci G; Paneni F; Passerini J; Volpe M
Expert Opin Pharmacother; 2012 Dec; 13(18):2687-97. PubMed ID: 23170911
[TBL] [Abstract][Full Text] [Related]
15. Hypertension management: rationale for triple therapy based on mechanisms of action.
Neutel JM; Smith DH
Cardiovasc Ther; 2013 Oct; 31(5):251-8. PubMed ID: 23121769
[TBL] [Abstract][Full Text] [Related]
16. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
[TBL] [Abstract][Full Text] [Related]
17. Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study.
Drummond W; Sirenko YM; Ramos E; Baek I; Keefe DL
Am J Cardiovasc Drugs; 2011 Oct; 11(5):327-33. PubMed ID: 21846154
[TBL] [Abstract][Full Text] [Related]
18. Aliskiren/amlodipine (Tekamlo): another combination tablet for hypertension.
Med Lett Drugs Ther; 2010 Nov; 52(1352):94-5. PubMed ID: 21116232
[No Abstract] [Full Text] [Related]
19. Azilsartan, aliskiren, and combination antihypertensives utilizing renin-angiotensin-aldosterone system antagonists.
Lanier G; Sankholkar K; Aronow WS
Am J Ther; 2014; 21(5):419-35. PubMed ID: 22975662
[TBL] [Abstract][Full Text] [Related]
20. Aliskiren/amlodipine combination for the treatment of hypertension.
Billecke SS; Marcovitz PA
Drugs Today (Barc); 2011 Jun; 47(6):403-17. PubMed ID: 21695283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
